Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Metastatic Breast Cancer Market Outlook

Thelansis’s “Metastatic Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Breast Cancer Overview

Breast cancer, particularly hormone receptor-positive (HR+) and HER2-negative (HER2-) subtypes, stands as the predominant malignancy affecting young women globally, constituting roughly 30% of new cancer diagnoses and accounting for 25% of cancer-related deaths. The prognosis and clinical trajectory of metastatic breast cancer patients are highly variable, influenced by diverse factors, including patient characteristics such as age and existing health conditions, as well as tumor attributes like hormone receptor status, tumor grade, and site of metastasis. Although the median survival period for metastatic breast cancer is typically 2-4 years, specific subgroups may experience extended survival, particularly those with less aggressive or localized metastatic disease. Initial diagnosis reveals metastatic spread in about 6%-10% of cases. Despite advancements in treatment strategies for metastatic breast cancer, the impact on overall survival remains modest. Presently, metastatic breast cancer is largely deemed incurable, with treatment primarily aimed at palliation. Nevertheless, the emergence of novel therapeutic agents has spurred efforts to prolong survival in this setting. Treatment protocols vary depending on the molecular subtype of breast cancer. HER2-positive patients typically receive trastuzumab in combination with pertuzumab and a taxane in the first-line setting, while trastuzumab emtansine is preferred in the second line. Hormone receptor-positive and HER2-negative patients are typically treated with hormone therapy alone or in combination with a CDK inhibitor, such as palbociclib, in the first line, and subsequent lines may include hormone therapy with or without a CDK4/6 inhibitor, irrespective of BRCA status. For triple-negative breast cancer (TNBC) patients with PD-L1 expression, atezolizumab combined with nab-paclitaxel has rapidly gained acceptance as the standard first-line therapy following its approval in August 2019. Taxane-based regimens are commonly employed for TNBC patients lacking PD-L1 expression.

• In the United States, an estimated 4.1 million women have a history of breast cancer, with approximately 4% of them living with metastatic disease. Alarmingly, over half of these individuals were initially diagnosed with early-stage (stages I-III) cancers.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: